ascopubs.org16h
Whole-slide multiplexed tissue imaging of prostate adenocarcinoma to investigate immune niches in high- versus low-grade tumors.
Developing a deep learning algorithm for automated p53 immunohistochemistry digital image analysis in prostate cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers ...
ascopubs.org2d
Management of relapsed stage I seminomatous germ cell tumor with retroperitoneal or pelvic only relapse.
Clinical outcomes of stage IIA/IIB seminoma treated with radiotherapy and chemotherapy: Should regional therapy be considered the preferred treatment approach?
ascopubs.org4d
Use of geospatial analysis with multiplex immunofluorescence to analyze tumor immune microenvironment patterns and prognosis in penile cancer.
Progressive T cell exhaustion and predominance of aging tissue associated macrophages with advancing disease stage in penile squamous cell carcinoma.
ascopubs.org4d
Reply to: Enfortumab Vedotin: A Promising Therapy for Head and Neck Cancer With Potential Links to Human Papillomavirus
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...
ascopubs.org5d
Safety and efficacy of FGFR inhibitors in urothelial carcinoma: A systematic review and meta-analysis.
The role of salvage cystectomy after prior trimodality therapy. This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers Symposium. This abstract does not include a full text ...
ascopubs.org5d
Impact of loss of PRLHR on aneuploidy and initiation of bladder cancer.
DNA damage repair alterations as predictive biomarker for platinum-based chemotherapy in metastatic urothelial cancer.
ascopubs.org5d
Protein analysis of urachal carcinoma tissue based on different antibody-drug conjugate therapeutic targets.
CD39 expression as a predictive biomarker for neoadjuvant treatment in muscle-invasive bladder cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers Symposium. This ...
ascopubs.org5d
A prospective provincial registry of PSMA PET CT for recurrent prostate cancer (PREP): Results for 4135 men.
[99mTc]Tc-iPSMA SPECT/CT as an alternative to PET imaging for decision making in prostate cancer patients. PREP registry: Key findings. Total (n=4135) Cohort 1 (n=255): BF within 3 months from RP and ...
ascopubs.org5d
Evaluation of systemic therapy and surgical consolidation in patients with node positive upper tract urothelial carcinoma.
A phase 2 trial of risk enabled therapy after neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancer (RETAIN-2).
ascopubs.org5d
Innovative diagnostic approaches: Serum protein markers in renal cell carcinoma.
Systemic therapies in renal cell carcinoma with brain metastases: A comparative meta-analysis of immunotherapy and tyrosine kinase inhibitors. PSMA-positive tumor vessels around renal cell carcinoma ...
ascopubs.org5d
Genomic characteristics of patients with metastatic hormone-sensitive prostate cancer treated with ARPI-based therapy: A single-center analysis.
Integrating aggressive variant prostate cancer–associated tumor suppressor genes (AVPC-TSG) status to refine prognosis and predict androgen-receptor pathway inhibitors (ARPI) response in metastatic ...
ascopubs.org5d
Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma
COSMIC-021 Phase Ib Study of Cabozantinib Plus Atezolizumab: Results from the Locally Advanced or Metastatic Urothelial Carcinoma Cohorts Data were from a retrospective chart review of patients with ...